Vyvanse™ (lisdexamfetamine dimesylate, NRP104) has been developed by New River Pharmaceuticals using its Carrierwave™ technology, which attaches an API to an adjuvant to create a pharmacologically inactive molecule. Lisdexamfetamine itself is a prodrug of amphetamine, and consists of amphetamine attached to lysine.